
March 11 (Reuters) - Viking Therapeutics Inc VKTX.O:
VIKING THERAPEUTICS SIGNS BROAD MANUFACTURING AGREEMENT WITH CORDENPHARMA TO SUPPORT COMMERCIALIZATION OF VK2735
VIKING THERAPEUTICS INC - VIKING TO MAKE PREPAYMENTS TOTALING $150 MILLION BETWEEN 2025-2028
VIKING THERAPEUTICS INC - CORDENPHARMA WILL PROVIDE FILL/FINISH CAPACITY FOR BOTH INJECTABLE AND ORAL FORMULATIONS OF VK2735
VIKING THERAPEUTICS INC - PLANS TO INITIATE PHASE 3 DEVELOPMENT WITH SUBCUTANEOUS FORMULATION OF VK2735 IN Q2 OF 2025.
VIKING THERAPEUTICS INC - AGREEMENT PROVIDES ANNUAL CAPACITY OF OVER ONE BILLION ORAL VK2735 TABLETS.